A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets

Transfusion

Volumn 55, Issue 8, 2015, Pages 1856-1865

  MacLennan, Sheila ^a   Harding, Kay ^a   Llewelyn, Charlotte ^a   Choo, Louise ^b   Bakrania, Lekha ^a   Massey, Edwin ^a,c   Stanworth, Simon ^d   Pendry, Kate ^a,e   Williamson, Lorna M ^f  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f NHSBT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; APHERESIS; ARTICLE; BLEEDING; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION REACTION; BRAIN HEMORRHAGE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; FOLLOW UP; HEART ARREST; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RASH; SECONDARY ANALYSIS; SUBDURAL HEMATOMA; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ADVERSE EFFECTS; AGED; BACTEREMIA; BLOOD; BLOOD STORAGE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HEMORRHAGE; MEDICAL DEVICE CONTAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADULT; AGED; BACTEREMIA; BLOOD; BLOOD PRESERVATION; BONE MARROW TRANSPLANTATION; CROSS-OVER STUDIES; EQUIPMENT CONTAMINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84938965178     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13038     Document Type: Article

References (29)

1. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
2. The Blood Safety and Quality Regulations 2005 No. 50 [Internet]. Surrey: The National Archives; 2005 [cited 2014 Dec 12]. Available from: http://www.legislation.gov.uk/uksi/2005/50/pdfs/uksi-20050050-en.pdf.
3. Blajchman MA, Goldman M, Baeza F., Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004; 18: 11-24.
4. Tomasulo P, Su L., Is it time for new initiatives in the blood center and/or the hospital to reduce bacterial risk of platelets? Transfusion 2011; 51: 2527-33.
5. Cardigan R, Williamson LM., The quality of platelets after storage for 7 days. Transfus Med 2003; 13: 173-87.
6. Dumont LJ, AuBuchon JP, Whitley P, et al., Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002; 42: 847-54.
7. AuBuchon JP, Taylor H, Holme S, et al., In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers. Transfusion 2005; 45: 1356-61.
8. Shanwell A, Diedrich B, Falker C, et al., Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion 2006; 46: 973-9.
9. Slichter SJ, Bolgiano D, Jones MK, et al., Viability and function of 8-day-stored apheresis platelets. Transfusion 2006; 46: 1763-9.
10. Slichter SJ, Bolgiano D, Corson J, et al., Extended storage of autologous apheresis platelets in plasma. Vox Sang 2013; 104: 324-30.
11. Slichter SJ, Davis K, Enright H, et al., Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-14.
12. Triulzi DJ, Assmann SF, Strauss RG, et al., The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012; 119: 5553-62.
13. Heuft HG, Goudeva L, Krauter J, et al., Effects of platelet concentrate storage time reduction in patients after blood stem cell transplantation. Vox Sang 2013; 105: 18-27.
14. Diedrich B, Ringden O, Watz E, et al., A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients. Vox Sang 2009; 97: 254-9.
15. Dijkstra-Tiekstra MJ, Pietersz RN, Hendriks EC, et al., In vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days. Transfusion 2004; 44: 330-6.
16. Miller AB, Hoogstraten B, Staquet M, et al., Reporting Results of cancer treatment. Cancer 1981; 47: 207-14.
17. Stanworth SJ, Estcourt LJ, Powter G, et al., A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013; 368: 1771-80.
18. Heddle NM, Cook RJ, Blajchman MA, et al., Assessing the effectiveness of whole blood-derived platelets stored as a pool: a randomized block noninferiority trial. Transfusion 2005; 45: 896-903.
19. McDonald CP, Pearce S, Wilkins K, et al., Pall eBDS: an enhanced bacterial detection system for screening platelet concentrates. Transfus Med 2005; 15: 259-68.
20. McDonald CP, Roy A, Lowe P, et al., Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates. Vox Sang 2001; 81: 154-60.
21. Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee (JPAC). Guidelines for the blood transfusion services in the UK. 8th ed. Norwich: JPAC; 2013 [cited 2014 Dec 12]; p 169-72. Available from: http://www.transfusionguidelines.org.uk/Index.aspx?Publication=RB&Section=25&pageid=8072.
22. Heddle NM, Blajchman MA, Meyer RM, et al., A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42: 556-66.
23. Heddle NM, Arnold DM, Boye D, et al., Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48: 1447-58.
24. Tang ML, Tang NS, Chan IS, et al., Sample size determination for establishing equivalence/noninferiority via ratio of two proportions in matched-pair design. Biometrics 2002; 58: 957-63.
25. Kerkhoffs JL, van Putten WL, Novotny VM, et al., Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
26. Arnold DM, Lim W., The use and abuse of surrogate endpoints in clinical research in transfusion medicine. Transfusion 2008; 48: 1547-9.
27. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-9.
28. Schiffer CA, Anderson KC, Bennett CL, et al., Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.
29. Schiffer CA, Lee EJ, Ness PM, et al., Clinical evaluation of platelet concentrates stored for one to five days. Blood 1986; 67: 1591-4.